<DOC>
	<DOCNO>NCT00222053</DOCNO>
	<brief_summary>Principal objective evaluate impact Thalidomide prolong duration response autologous transplantation myeloma</brief_summary>
	<brief_title>IFM 99-02 Thalidomide Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>de novo myeloma accord Durie Salmon classification stage II , III stage I lytic bone lesion patient 18 65 year old beta2microglobulin &lt; 3 mg/l del13 absent sign informed consent eligible transplantation peripheral neurological toxicity uncontrolled severe cardiovascular disease malignancy except basocellular carcinoma FIGO stage I carcinoma cervix patient receive biphosphonate last 60 day renal failure definited creatinine &gt; 150 µmol/l patient obvious vascular cerebral medical history liver dysfunction definited bilirubin &gt; 35 µmol/l ASAT , ALAT , PAL &gt; 4N respiratory dysfunction HIV + Patient refuse use acceptable barrier method contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Autologous transplantation</keyword>
	<keyword>Maintenance therapy</keyword>
	<keyword>Thalidomide</keyword>
</DOC>